DOMAIN Therapeutics

🌟Our team has secured 8th place out of 246 participants in our category in the 15th anniversary edition of the "Bike to Work" challenge (Au boulot à vélo)! That’s a leap forward from last year, getting closer to the top finalists! Way to go TEAM 👏 🏆 We are extremely proud to share with you our remarkable results 😊 -we’ve cycled an impressive 6,691.83 kilometers. Imagine cycling from Paris to Chicago, IL that’s the distance we’ve covered! 🌎🌱 -by swapping our cars for bikes, we’ve collectively reduced our carbon footprint by approximately 1,500 kg of CO2. That’s equivalent to the CO2 absorbed by 75 trees in a year or powering 29387 online searches. 🌳 🚲💚Many of our colleagues have embraced the joy of cycling to work or use public transport all year around. This challenge has not only highlighted our #teamspirit and the environmental benefits of our daily commutes but also underscored the health-conscious culture that thrives within our company. At Domain Therapeutics, our commitment to sustainability goes beyond our cutting-edge innovation in GPCR-targeting therapies. It’s reflected in our everyday actions and choices, embodying our mission to make a real difference for our local and global communities. 🌏 We take pride in our #softmobility policy, which promotes eco-friendly transportation options and facilitates sustainable commuting for our team. Choosing to cycle to work is not just practical and economical, but it’s also a fun, energizing and eco-responsible alternative that can make a real impact on our planet. A big thank you to everyone who participated and supported this initiative!  Check out the video capturing our enthusiasm, cycling and summertime vibes! Let's keep this momentum going, both on and off the bike, as we enjoy the outdoors and stride towards a greener, healthier, and more sustainable future together! #sustainabilitymatters #teamspirit #challengeaccepted Ville et Eurométropole de Strasbourg

A week of discovery and progress at Domain! Last week our company headquarters were buzzed with excitement as we hosted our Science Day, and had the honor of welcoming our Board of Directors. These successful events showcased our progress and celebrated the collective efforts of our incredible team to bring solutions to patients facing therapeutic failure in the clinic. With over two decades of solid expertise in GPCR #drugdiscovery, Domain is pioneering GPCR therapeutic target identification and cutting-edge science to harness the power of the immune system and deliver therapeutic solutions to patients in the clinic. We are committed to addressing complex diseases by combining patient-centricity and #innovation, driving change and providing the unprecedented access to precision-enabled immunotherapies. Our Science Day was a vibrant platform to present our precision research, the depth of our know-how and experience of our Domain' team to advance our robust pipeline of disruptive assets. GPCRs, instrumental in drug discovery and accounting for 30% of all marketed drugs, hold immense therapeutic potential. Yet, their full potential remains largely untapped. At Domain, we are on a mission to change that. Our innovative approach focuses on uncovering new and even intractable GPCR targets, transforming GPCR drug discovery into life-changing medicines for patients worldwide. Last week’s events were a great illustration of the scientific productivity and research quality at Domain, reflecting the dynamic atmosphere within our research environment. It was incredibly inspiring to see how aligned our investors are with our goals. Their unwavering support, strategic insights experience and proven track record across various sectors are propelling our development forward. As Domain continues to play a pivotal role in within the biotech and pharmaceutical industry, the collective expertise of our Board of Directors and our highly experienced team fuels our determination to drive innovation and excellence in our therapeutics solution offerings. We extend our heartfelt thanks to Roberto De Ponti, Laurence Rulleau,PhD, Sylvie Ryckebusch, James Huang, Frederic Lemaitre Auger and Erwin Boos for their invaluable contributions and to everyone else who made our recent events a success! Together, we are unlocking GPCR potential into tangible achievements for a better tomorrow. #drugdevelopment #precisionmedicine #immunotherapy

🚴♂️ 🚴♀️ This June, team Domain is once again rising to the challenge of Bike to work (Au boulot à vélo)! Every kilometer cycled, whether commuting, attending meetings, business trips, or even working from home, contributes to our collective goal. It’s simple: we’re swapping four wheels for two! 🚴♀️ 🚴♂️ What if your daily commute could boost your health, team spirit and save the planet? 😉  👉 #HealthAndWellness. Cycling to work keeps us fit, energized and ready to tackle the day!  👉 #EnvironmentalImpact. By choosing bikes over cars, we are reducing pollution and easing urban traffic!  👉 #TeamSpirit. It isn’t just about the distance, it’s about the collective effort!  👉 #SustainabilityMatters. Cycling to work is one of the many ways we’re committed to protecting the environment, a commitment that is deeply embedded into our company’s DNA. 💚 Last year, we pedaled nearly 10,000 kilometers, securing the 9th spot out of 243 teams. That’s 2.53 tons of CO2 emissions avoided, equivalent to a trip from Paris to La Réunion! This year, we’re aiming to go even further. 💪 🙏 A big thank you to everyone representing our #biotech in this sporting and collaborative challenge. And guess what? Many of us at Domain don’t limit ourselves to just one month, we enjoy cycling year-round! So grab your helmets, oil those chains, and together, let’s pedal toward a healthier and greener future! 🌍 🌱 #sustainableliving #ChallengeAccepted

We’re thrilled to announce the publication of three international Patent Cooperation Treaty (PCT) patent applications that cover our groundbreaking series of Treg-depleting anti-CCR8 monoclonal antibodies, including our lead candidate DT-7012. By securing intellectual property rights across diverse markets, these new patents expand the geographic protection of our game-changing Treg depleting ADCC/ADCP CCR8 antibodies, underscoring their broad therapeutic application. And the timing couldn’t be better, our accelerated R&D efforts in #immunooncology align seamlessly with this PCT publication. The CCR8 GPCR target is specifically expressed by tumor infiltrating Tregs, key immunosuppressive cells within the tumor microenvironment (TME). Their presence compromises the efficacy of existing immunotherapies. Blocking CCR8 is a highly strategic approach in immuno-oncology, increasing clinical success rates in non-responding patients! DT-7012 is a novel anti-CCR8 monoclonal antibody that depletes tumor-infiltrated Tregs within the TME, leveraging ADCC/ADCP mechanisms. Compared to other clinical-stage anti-CCR8 antibodies, DT-7012 has a proven best-in-class potential in activating antitumor immunity for cancer patients unresponsive to other treatments and paving the way for the development of effective GPCR-targeting immunotherapies. As we forge ahead, pushing the boundaries of innovation in cancer treatment, we invite you to follow our progress. We’re committed to revolutionizing GPCR #drugdevelopment and broadening therapeutic options to improve clinical outcomes for cancer patients. #precisionmedicine #immunotherapy #techinnovation #GameChanger

Did you know that some skin conditions could be more than what they seem? This May, as we observe Skin #CancerAwareness Month, let’s shed light on rare cancers that affect the skin, such as cutaneous T-cell lymphoma (CTCL), which may be mistaken for noncancerous conditions, such as eczema and psoriasis, leading to delayed diagnosis and treatment. CTCL affects about one in 100,000 adults worldwide annually, nearly tripling in last 30 years. With a median survival rate of less than 5 years for advanced stages and no established standard-of-care, patients’ lives are profoundly impacted. That is why at Domain we are actively working to understand the underlying factors guiding disease progression. We’re exploring the tumor microenvironment in CTCL and the predictive biomarkers available for clinical use. With the support of ANR, the French National Research Agency as a part of #France2030 investment plan, we are part of the Hospital-University Research in Health (RHU) SPRINT aiming to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care. This consortium is at the beginning of the collaborative journey with world-class academics and highly innovative companies, including @Université Paris Cité Hospices Civils de Lyon - HCL Greater Paris University Hospitals - AP-HP CHU de Bordeaux INSERM TheraPanacea, and more. United in our commitment, we are pushing the boundaries of therapeutic innovation, bringing new hope to CTCL patients. We’re proud to contribute to this project with our innovative precision research and our novel drug candidate, DT-7012, a Treg depleting anti-CCR8 monoclonal antibody. This best-in-class candidate holds an immense potential to overcome Treg-mediated resistance to #immunotherapy, reshape the tumor microenvironment, and unlock the immune system’s cancer fighting abilities. #precisionmedicine #drugdiscovery #cancerresearch The Skin Cancer Foundation

As we mark the 250th year anniversary of the first randomised trial, it is a timely moment to reflect on the significant progress in #clinicalresearch and its monumental impact on human health. In the field of cancer treatment, the research journey has seen many successful therapeutic strategies and substantial innovation in #clinicaltrials and regulatory frameworks. Yet, the quest for a cure continues. This highlights the critical need for trials that are not only patient-centric, but also strategically planned, and executed with precision. Due to the heterogenous nature of cancer, its mechanisms of resistance remain a big challenge. At Domain, we’re dedicated to understanding these complexities to determine an optimal therapeutic strategy. We are at the forefront of developing novel treatments that target G Protein Coupled Receptor (GPCR) mediated immunosuppression. GPCRs have long been overlooked in cancer therapy, but their significance is now undeniable to advance innovation the field. They play a pivotal role in shaping immune responses against tumors and their modulation holds an immense promise to redefine cancer treatment. We apply thoughtful design to our trials, combining strategic GPCR therapeutic targets with comprehensive biomarkers, carefully selected patient sub-populations and robust data management to enhance trial efficiency and success rates aiming to turn non-responder cancer patients into responders. Our lead clinical candidate, DT-9081, the EP4R antagonist is moving towards Phase II trials and our groundbreaking Treg-depleting anti-CCR8 monoclonal antibody candidate, DT-7012, is expected to start Phase I trials in mid-2025. This progress would not be possible without the amazing dedication of our team, collaborations, innovation, and our shared passion for advancing therapeutic progress in cancer therapy. On the clinical trials day, and every day, we salute patients, clinicians, investigators and researchers whose unwavering efforts are revolutionising the cancer treatment landscape and paving a way to a healthier future for millions of people across the globe. Join us in this celebration of progress and hope. Together, let’s make a difference! #drugdevelopment #immunooncology #precisionmedicine

It was an absolute pleasure to welcome bioengineering students from Clemson University in South Carolina, United States, along with their respected faculty leader Dr. Heather Dunn! At Domain, we believe in the power of knowledge transfer. Our engagement was not just about the fascinating domains of #immunooncology, #cancerresearch and innovative #drugdevelopment techniques. It was about sparking a dialogue that bridges academia and industry, nurturing the next generation of biotech leaders. In line with this belief, our Vice President of Business Development and Communication Marjorie Sidhoum initiated the presentation introducing Domain Therapeutics as the leading GPCR immuno-oncology company, thereby setting the stage for a rich exchange of ideas and insights. Why focus on GPCRs in immuno-oncology to defeat cancer? Our Chief Scientific Officer Stephan Schann led an insightful session on this largest family of human receptors which play a pivotal role in modulating the immune system, tumor biology and the tumor microenvironment. The students learned that unlocking GPCR-mediated immunosuppression opens doors to groundbreaking therapeutic solutions, maximizing benefits to cancer patients worldwide. The hands-on experience continued with our Head of Clinical Operations Claire Jouffroy-Zeller who delved into DT-9081, a small molecule candidate targeting the EP4 receptor. By showcasing how a differentiated drug development process maximizes cancer treatment success rates, we provided the students with practical insights. Our chemistry and translational departments took center stage, offering the students an opportunity to discover benchwork side of our drug discovery process in our laboratories and interact with our passionate scientists Christelle Doebelin and María Dolores García Fernández. They glimpsed firsthand the precision-enabled science driving our innovation. The students’ curiosity sparked a flurry of interesting questions, reaffirming their passion for #biothechnology, healthcare and research. We are proud to share our innovative science to create a transformative impact that drives advancements in the industry. We extend our heartfelt thanks to the Cepa Foundation for facilitating this initiative and recognize our Domain team whose dedication and expertise are cornerstones of our success! To the students, we wish you a summer full of discovery and a future bright with innovation and success! #precisionmedicine #futureofhealthcare

Join us at BioEquity Europe in San Sebastián, Spain, May 12-14! Our CEO, Sean A. MacDonald will be taking the stage to shed light on our growing portfolio of innovative drug candidates, specifically designed to fight the ever-evolving challenge of cancer immunoresistance in the tumor-microenvironment. How can we overcome cancer resistance and pave the way to more effective therapeutic strategies that offer maximum benefit patients? Sean will delve into this critical question and more in his comprehensive presentation on May 13 at 11:45 AM CET (Room 4+5 Kursaal Congress Centre, Roadshow Track dedicated to Cancer) and is eager to connect with passionate venture funds engaged in leveraging innovation for the benefit of cancer patients. With over two decades of solid expertise, an innovative patient-centered approach and our proprietary GPCR targeting #drugdiscovery platform, Domain is leading the change in cancer innovation. Our commitment has led to a unique pipeline of first-in-class and best-in-class treatments targeting GPCR-mediated immunosuppression, featuring: A clinical stage valuable candidate: DT-9081, a small molecule targeting the EP4 receptor, currently in Phase I clinical trials Two pre-IND stage candidates: DT-7012, an anti-CCR8 Treg-depleting monoclonal antibody DT-9045, a first-in-class small molecule PAR2 receptor antagonist This is a unique opportunity to learn about the exciting advances that our dedicated team has made in precision #immunotherapy. We are on a mission to turn our GPCR-targeting innovation into transformative treatments for cancer patients worldwide. Be part of the dialogue that’s defining the next wave of clinical development of our pioneering #immunooncology assets. Don’t miss this chance to be at the forefront of cancer innovation. We look forward to seeing you there! #lifesciences #biopharma #InvestmentOpportunities BioCentury Inc. EBD Group

Great news! Our CEO, Sean A. MacDonald, will be participating in the highly anticipated LSX World Congress, taking place this April 29-30 in London, UK! Don't miss Sean'presentation on Monday as he will share Domain Therapeutics' exciting advancements in precision medicine for cancer treatment. At Domain, we're not just pioneering innovative therapies. We're redefining what's possible in the fight against cancer. Through our unwavering commitment to leveraging G Protein-Coupled Receptors (GPCRs) in immuno-oncology, we unlock new possibilities to beat resistance and defeat cancer. If you'll be participating in this premier gathering of industry leaders and investors, don't miss this valuable opportunity to connect with Sean and discuss Domain Therapeutics' very hot targets and our innovative approach to cancer therapy. Let's ignite conversations, forge partnerships, and drive global innovation in healthcare together. See you at LSX - partnering for Life Science eXecutives World Congress! #PrecisionMedicine #Immunooncology #Biotech #Innovation #Fundraising

Every year the #EarthDay is a reminder for all of us to appreciate and preserve the beautiful world we live in. It’s time for introspection about the impact we have on our planet. At Domain Therapeutics, we recognize that managing waste and reducing our environmental footprint is a challenge that requires more than just a single day’s attention. As dynamic actors in #biopharma industry, we are committed to advancing scientific innovation. We aim to transform this innovation into therapeutic progress in cancer treatment for the maximum benefit to patients. We are equally dedicated to integrating sustainable practices into every facet of our work. This means actively identifying and implementing measures that not only reduce waste but also enhance resource efficiency. Our recent initiatives are a testament to this commitment. We have taken a step to repurpose some of our laboratory materials and equipment, such as glassware, furnitures and books to support local educational institutions IPMC and ECPM Ecole européenne de chimie polymères et matériaux de Strasbourg. These actions are part of our broader vision to foster a culture of sustainability that empowers future generations. This Earth Day let’s celebrate the tangible actions that contribute to a healthier planet. Our journey towards sustainable development is ongoing and we are exploring the innovative approaches in #drugdiscovery that are both effective and environmentally conscious. Take a moment to consider how you can contribute to environmental conservation in your own community. Together, we can make a difference today and create a sustainable tomorrow. #drugdevelopment #immunooncology #immunotherapy #sustainability